In summary we have developed an in vivo A29 lymphoma model in which stable Foxp1 depletion by CRISPR/Cas9 genome editing delayed in vivo lymphoma growth and appeared to be curative in a subgroup of animals. This evidence concerns the gene FOXP1 and lymphoma.